Strokes are perhaps the most serious complications of sickle cell disease (SCD) and by the fifth decade occur in approximately 25% of patients. While most patients do not develop strokes, mounting evidence indicates that even without brain abnormalities on imaging studies, SCD patients can present profound neurocognitive dysfunction. We sought to evaluate the neurocognitive behavior profile of humanized SCD mice (Townes, BERK) and to identify hematologic and neuropathologic abnormalities associated with the behavioral alterations observed in these mice. Heterozygous and homozygous Townes mice displayed severe cognitive deficits shown by significant delays in spatial learning compared to controls. Homozygous Townes also had increased depression-and anxiety-like behaviors as well as reduced performance on voluntary wheel running compared to controls. Behavior deficits observed in Townes were also seen in BERKs. Interestingly, most deficits in homozygotes were observed in older mice and were associated with worsening anemia. Further, neuropathologic abnormalities including the presence of large bands of dark/pyknotic (shrunken) neurons in CA1 and CA3 fields of hippocampus and evidence of neuronal dropout in cerebellum were present in homozygotes but not control Townes. These observations suggest that cognitive and behavioral deficits in SCD mice mirror those described in SCD patients and that aging, anemia, and profound neuropathologic changes in hippocampus and cerebellum are possible biologic correlates of those deficits. These findings support using SCD mice for studies of cognitive deficits in SCD and point to vulnerable brain areas with susceptibility to neuronal injury in SCD and to mechanisms that potentially underlie those deficits.
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Introduction
Cerebrovascular accidents are serious complications in sickle cell disease (SCD) patients and occur in 5 to 10% of children and approximately 25% of adults by the fifth decade of life (Helton et al., 2014; Ohene-Frempong et al., 1998; Vichinsky et al., 2010) . Moreover, approximately 22% of SCD children also develop silent strokes, which are evident on magnetic resonance imaging but are not associated with overt clinical neurologic deficits (DeBaun et al., 1998) . As a consequence of overt or silent strokes, SCD patients can have global neurocognitive impairment as well as sensory and motor deficits (DeBaun et al., 1998) . However, there is mounting evidence to suggest that even in the absence of overt cerebrovascular disease and/or parenchymal cerebral abnormalities on imaging studies, children and adults with SCD who are neurologically intact can still have profound neurocognitive dysfunction (Vichinsky et al., 2010; Wang et al., 2001) . Researchers showed that nearly 20% of infants and toddlers with SCD score more than two standard deviations below the normal control mean on cognitive and motor neurodevelopmental evaluations (Glass et al., 2013) . Further, some SCD patients without cerebrovascular accidents also show reduced performance in standard global cognitive function, working memory, processing speed and executive function tests (Steen et al., 2003; Vichinsky et al., 2010; Wang et al., 2001 ). Therefore, a great deal of evidence indicates that central nervous system dysfunction is highly prevalent among SCD patients and can present as significant neurocognitive deficits. 
